| Biomarker ID | 1143 |
| PMID | 23803082 |
| Year | 2013 |
| Biomarker | RFX6 (rs339331) |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Blood |
| Subjects | Humans |
| Regulation | Reduced Risk of Prostate cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 0.73 (95% CI: 0.57-0.94) |
| Effect on Pathways | Pathways include: PLK2 human kinase ARCHS4 coexpression, CAMK2D human kinase ARCHS4 coexpression, ACVR1C human kinase ARCHS4 coexpression, CDC42BPA human kinase ARCHS4 coexpression, MYO3A human kinase ARCHS4 coexpression |
| Experiment | Cancer Vs Normal |
| Type of Biomarker | Diagnostic |
| Cohort | All subjects were from Beijing and Tianjin, including 266 cases with prostate cancer and 288 normal individuals as controls. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p= 0.013 |
| Method Used | PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | RFX6 |